文献速递乳腺癌放疗

高危乳腺癌术后1周与2周大分割辅助放疗:急性毒性结果

HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-Risk Patients With Breast Cancer (HYPART): Acute Toxicity Results.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-08-06

HYPART研究将941例高危乳腺癌术后患者随机分配至1周26 Gy/5次或2周34 Gy/10次辅助放疗方案,比较急性毒性。结果显示两组总体急性毒性无显著差异,但1周方案吞咽困难发生率显著低于2周方案,表明1周区域淋巴结照射方案安全可耐受。

要点

  • 手臂疼痛、水肿及咳嗽发生率两组间无显著差异。

核心结论

  • 1周大分割辅助放疗方案在高危乳腺癌患者中安全可耐受,吞咽困难发生率低于2周方案。

研究设计与样本

  • HYPART研究为随机对照试验,纳入2020年10月至2024年6月期间941例高危乳腺癌术后患者,随机接受1周26 Gy/5次或2周34 Gy/10次放疗,保乳手术患者加量8 Gy/2次/2天,采用二维或三维技术,按RTOG标准评估急性毒性。

关键数值与推荐

  • 1周方案为26 Gy分5次,2周方案为34 Gy分10次,保乳术后加量8 Gy分2次。

临床怎么用

  • 1周大分割辅助放疗方案可用于高危乳腺癌术后区域淋巴结照射,急性毒性可接受,吞咽困难更少。

局限性

  • 本文仅报告急性毒性结果,未涉及晚期毒性及疗效数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The HYPofractionated Adjuvant RadioTherapy study aimed to compare a 1-week adjuvant radiation therapy (RT) schedule with a 2-week schedule in high-risk patients with breast cancer. Here we present the acute toxicity data of the study. METHODS AND MATERIALS: The HYPofractionated Adjuvant RadioTherapy study was approved by the institutional ethics committee and was registered with ClinicalTrials.gov ID NCT04472845 and CTRI with REF/2020/09/037050. Patients with high-risk breast cancer after mastectomy or breast conserving surgery were randomized to receive an RT dose of 26 Gy in 5 fractions over 1 week or 34 Gy in 10 fractions over 2 weeks. Patients who underwent breast conserving surgery received a sequential or simultaneous integrated boost with a dose of 8 Gy/2#/2 days. Patients were planned and treated with a 2-dimensional or 3-dimensional technique. Acute radiation toxicities were assessed according to the Radiation Therapy Oncology Group grading system. RESULTS: A total of 941 patients treated between October 2020 and June 2024 were included in this analysis. Acute toxicity grade 0, 1, 2, and 3 with 1 week and 2 week schedules were observed in 265 (55%) versus 248 (54%), 141 (29.3%) versus 155 (33.8%), 73 (15.1%) versus 54 (11.8%), and 3 (0.6%) versus 2 (0.4%) patients (P = .282), respectively. Dysphagia was reported as grade 0, 1, and 2 in 461 (95.6%) versus 413 (90%), 14 (2.9%) versus 41 (8.9%), and 7 (1.5%) versus 5 (1.1%) patients with a 1-week and 2-week schedule (P = .001), respectively. Grade 1 and 2 arm pain was observed in 8 (1.6%) versus 8 (1.7%) and 7 (1.5%) versus 4 (0.9%) patients with a 1-week and 2-week schedule (P = .753), respectively. Acute arm edema was grade 1 and 2 in 100 (20.8%) versus 81 (17.6%), and 20 (4.1%) versus 28 (6.1%) patients in the 1-week and 2-week schedule (P = .227), respectively. Grade 1 and 2 cough was reported in 5 (1.0%) versus 2 (0.4%) and 4 (0.8%) versus 3 (0.7%) patients in the 1-week and 2-week schedule (P = .700), respectively. CONCLUSIONS: Dysphagia was less with the 1-week RT schedule as compared to the 2-week schedule. The trial showed the safety and tolerability of a 1-week regional nodal irradiation course and provided toxicity rates that will help future studies in sample size calculations.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Yadav BS, Goyal S, Dahiya D, et al. HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-Risk Patients With Breast Cancer (HYPART): Acute Toxicity Results. Int J Radiat Oncol Biol Phys. 2025. PMID: 40780546. doi:10.1016/j.ijrobp.2025.07.1447

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。